Mitochondrial Function and Recovery Capacity: Toward a New Biology of Aging

MITO RISING | RECOVERY SCIENCE | October 2026

From mitochondrial dysfunction to Mitochondrial Recovery Medicine (MRM)

Shigeki Takemoto, MD, PhD

MitoQure / mitoqure.org

1. The central proposition: Mitochondria determine how effectively life responds to stress

Mitochondria have traditionally been described as the powerhouses of the cell. Although correct, this description captures only a fraction of their biological significance.

Mitochondria do not simply supply energy for cellular activity. They help determine whether a cell can respond appropriately to injury, coordinate repair, resolve stress responses, and restore functional homeostasis.

This distinction is fundamental to the Recovery Capacity Theory proposed within MITO RISING:

Aging is not simply the passage of time. Aging is the progressive loss of our capacity to recover.

From this perspective, mitochondrial function is not merely a determinant of physical energy or metabolic efficiency. It is a potential central regulator of biological recovery.

A young, metabolically adaptable cell can often tolerate stress, repair damage, renew its components, and return to an appropriate functional state.

An aging cell may survive the same stress but fail to recover completely. Damage accumulates, inflammation persists, and functional capacity gradually declines.

The difference is not necessarily the amount of initial damage. It may be the efficiency, completeness, and timing of the recovery response.

This suggests a broader hypothesis:

Mitochondrial health is better understood as the capacity to maintain, adapt, and restore cellular function than as ATP production alone.

Importantly, mitochondria are not the sole determinants of recovery. Nuclear DNA integrity, immune coordination, tissue stem cells, vascular function, neuroendocrine regulation, and social and behavioral factors also contribute. The proposal that mitochondria integrate many of these processes is a promising scientific framework, not yet a fully validated unified theory.

2. Six mitochondrial functions essential for recovery

2.1 Bioenergetics: ATP as the operational currency of repair

Almost every major recovery process requires energy, including protein synthesis, DNA repair, ion-gradient restoration, membrane transport, immune-cell activation, and tissue remodeling.

Mitochondrial oxidative phosphorylation generates much of the ATP required for these activities.

During recovery from an infection, for example, ATP supports immune-cell activation, damaged-cell removal, and the restoration of tissue function.

In aging, impaired electron transport, altered mitochondrial membrane potential, reduced respiratory reserve, and disrupted substrate utilization can diminish this ability.

A particularly important concept is spare respiratory capacity: how much mitochondrial respiration can increase above its baseline level when demand rises.

Two individuals may maintain similar energy levels at rest, yet respond very differently to the same physical stress.

One can rapidly increase mitochondrial ATP production, whereas the other has insufficient reserve.

This may help explain why normal resting measurements do not always predict resilience during illness or exertion.

2.2 Redox signaling: Damage versus adaptation

Mitochondria generate reactive oxygen species (ROS), including superoxide and hydrogen peroxide.

ROS have dual functions.

At physiological levels, they act as signals that promote adaptation, immune responses, antioxidant defense, and mitochondrial biogenesis.

At excessive or poorly controlled levels, they contribute to damage involving mitochondrial DNA, membrane lipids, and proteins.

The challenge is therefore not to eliminate mitochondrial ROS completely.

It is to maintain appropriate redox signaling and restore balance after stress.

This is relevant to interventions such as molecular hydrogen and mitochondria-targeted antioxidants. Reducing oxidative stress indiscriminately may interfere with beneficial adaptations, including certain exercise-induced responses.

Thus, recovery requires regulation of redox signaling, not simply maximal antioxidant activity.

2.3 Mitochondrial quality control: Mitophagy, fusion, and fission

Mitochondria form dynamic networks that undergo fusion, fission, and selective removal.

Key processes include:

• Mitophagy: Removes dysfunctional mitochondria through lysosomal degradation, involving pathways such as PINK1–Parkin and BNIP3/NIX.
• Fusion: Mediated partly by MFN1, MFN2, and OPA1, allowing mitochondrial contents to mix and supporting network integrity.
• Fission: Involving DRP1 and associated proteins, enables network remodeling and can facilitate the separation of damaged mitochondrial regions.
• Biogenesis: Involving regulators such as PGC-1α, NRF1/2, and TFAM, supports replacement and expansion of mitochondrial capacity.

Aging can disrupt the coordination of these processes.

Importantly, simply increasing mitophagy is not always beneficial. If mitochondrial removal outpaces replacement, the cell may lose functional mitochondrial mass.

The therapeutic objective is to improve mitochondrial turnover and quality control as an integrated system.

2.4 Mitochondrial–immune communication

One of the most important developments in aging biology is recognizing mitochondria as regulators of innate immunity.

Under conditions of cellular injury, mitochondrial DNA (mtDNA) can escape into the cytosol or extracellular environment.

Cytosolic mtDNA can activate the cGAS–STING signaling pathway, leading to inflammatory signaling through TBK1, IRF3, and NF-κB.

Acute activation can contribute to host defense. Persistent or inappropriate activation can promote inflammatory dysregulation.

This creates a potential link between mitochondrial dysfunction and inflammaging.

This pathway is particularly relevant to Recovery Capacity Theory because inflammation may persist after the original injury has subsided.

The critical question becomes:

Can the organism terminate an appropriate stress response once its purpose has been fulfilled?

2.5 Metabolic flexibility: The ability to change energy strategy

Healthy mitochondria help cells transition between glucose oxidation, fatty-acid oxidation, and other metabolic substrates according to their needs.

Immune cells, for example, undergo metabolic remodeling during activation, proliferation, differentiation, and the return toward homeostasis.

These transitions are not uniform: different immune-cell subsets require distinct metabolic programs.

Aging-related mitochondrial dysfunction can impair metabolic flexibility, contributing to insulin resistance, muscle fatigue, immune dysfunction, and reduced adaptability.

Recovery therefore involves not only obtaining sufficient energy but also deploying the appropriate metabolic program at the appropriate moment.

2.6 Cell renewal and intercellular mitochondrial communication

Mitochondrial function influences stem-cell quiescence, activation, differentiation, and survival.

Emerging research also indicates that mitochondria or mitochondrial components can sometimes move between cells through mechanisms involving tunneling nanotubes or extracellular vesicles.

In experimental models, such transfers may support injured cells or alter immune function.

However, these mechanisms remain highly context-dependent. Mitochondrial transfer can also support undesirable processes, including tumor survival.

Therapeutic mitochondrial transfer remains investigational and should not yet be regarded as an established treatment for age-related decline.

3. How mitochondrial dysfunction produces age-related decline

Mitochondrial decline is not a single event. It is a progressive failure of interconnected adaptive processes.

These relationships are mechanistic contributors, not one-to-one diagnostic rules. Fatigue, inflammation, and functional decline have many possible causes.

Aging as incomplete recovery

A useful way to interpret age-related decline is that damage and repair become progressively imbalanced.

Healthy adaptation versus progressive recovery failure

In the effective response, damage produces a transient decrease in function, followed by coordinated repair and near-complete restoration.

In the impaired response, inflammation may remain active, damaged mitochondria accumulate, and functional recovery is delayed or incomplete.

Repeated episodes of incomplete recovery could progressively reduce the functional reserve available for future challenges.

This suggests that chronic age-related decline may sometimes reflect the cumulative consequences of unsuccessful recovery episodes rather than damage accumulation alone.

The model is particularly valuable because it leads to measurable predictions about recovery kinetics.

4. Therapeutic strategies for restoring mitochondrial recovery capacity

The therapeutic landscape can be organized into five objectives:

1. Improve mitochondrial energy production and metabolic adaptability.
2. Remove dysfunctional mitochondria and renew the mitochondrial network.
3. Restore appropriate redox and stress signaling.
4. Reduce mitochondrial-driven persistent inflammation.
5. Translate improvements in mitochondrial biology into meaningful functional recovery.

The important distinction is between mitochondrial target engagement and demonstrated improvement in human recovery. Many experimental compounds achieve the first without yet establishing the second.

4.1 Exercise: The most established mitochondrial intervention

Exercise remains the most clinically actionable method for improving mitochondrial function in aging.

Endurance training activates pathways involving AMPK, CaMK, and PGC-1α and can increase mitochondrial content, oxidative capacity, and metabolic flexibility.

Resistance training stimulates muscle protein synthesis and may also improve mitochondrial dynamics, respiratory function, and quality control.

A 2024 meta-analysis of 38 randomized trials involving 1,682 middle-aged and older adults found that aerobic training had greater effects on cardiorespiratory fitness and six-minute walking distance, whereas resistance training better supported lean body mass. Combining these forms of exercise offers complementary benefits.

A 2025 study also reported improvements in mitochondrial respiratory capacity and redox-related measures following combined resistance and high-intensity interval training in aging adults.

For Recovery Capacity Theory, exercise is particularly interesting because it uses controlled stress to induce an adaptive response.

This is the principle of mitohormesis.

A moderate, recoverable challenge activates adaptive mechanisms, potentially improving the ability to tolerate subsequent challenges.

However, patients with frailty, cardiovascular disease, autonomic dysfunction, or post-exertional symptom exacerbation require individually adjusted programs. Greater exercise intensity is not invariably better.

4.2 NAD⁺ restoration: NMN and nicotinamide riboside

NAD⁺ plays essential roles in oxidative metabolism, redox reactions, DNA-damage responses, and signaling through enzymes such as sirtuins and PARPs.

Its availability is therefore relevant to multiple mitochondrial and recovery processes.

Potential mechanisms of NAD⁺ precursor supplementation include:

• Supporting NAD⁺-dependent metabolism.
• Influencing mitochondrial stress responses.
• Modulating pathways associated with mitochondrial biogenesis.
• Supporting selected cellular repair processes.

A 2026 systematic review in Ageing Research Reviews examined 113 preclinical and human studies, including 33 human intervention studies.

The review found that oral NAD⁺ precursors, including NMN and NR, generally increase NAD-related biomarkers, but clinical outcomes involving metabolic health, vascular function, and physical performance remain mixed. It also found no eligible anti-aging or wellness outcomes trials of intravenous or intramuscular NAD⁺ administration.

This leads to an important distinction:

An increase in circulating or tissue NAD⁺ is evidence of biochemical activity, not proof that recovery capacity has improved.

For MRM, NAD⁺ enhancement should be investigated as a potential means of supporting the cellular response to stress, with functional recovery measured as the outcome.

4.3 5-ALA: Heme biosynthesis and mitochondrial respiratory competence

5-Aminolevulinic acid (5-ALA) is a precursor in heme biosynthesis.

Heme is essential for several proteins involved in electron transport, oxygen utilization, and cellular metabolism, including cytochromes.

This provides a plausible mechanistic connection between 5-ALA availability and mitochondrial respiratory competence.

The proposed pathway is:

5-ALA availability → heme biosynthesis → respiratory-chain protein function → cellular bioenergetics.

Nevertheless, supplementation does not automatically improve mitochondrial respiration in individuals with adequate heme synthesis. The pathway is tightly regulated, and excessive precursor availability can have undesirable effects.

For aging-related recovery, evidence that supplemental 5-ALA produces meaningful clinical improvements remains insufficient. The approach should therefore be considered investigational for this indication.

Within the MITO RISING Three Arrows framework, 5-ALA can be positioned as a candidate capacity-supporting intervention, rather than an established method for restoring mitochondrial reserve.

4.4 Molecular hydrogen: Redox modulation and mitochondrial protection

Molecular hydrogen (H₂) has attracted research interest because of its potential effects on oxidative stress, inflammatory signaling, and cellular stress responses.

Proposed actions include modulation of redox-associated pathways, possible effects on NRF2 signaling, and attenuation of selected inflammatory processes.

An appealing aspect is the possibility of modulating rather than completely suppressing stress-associated signaling.

However, it is important not to overstate selectivity: hydrogen has not been conclusively established as a clinically selective scavenger of harmful radicals while preserving all beneficial ROS signaling.

Human studies involving exercise performance and fatigue have produced some encouraging results, but protocols vary considerably, and direct evidence that inhaled or ingested hydrogen restores mitochondrial function or reverses aging remains inadequate.

In an MRM research program, hydrogen is best considered a candidate protection and stress-response modulation strategy.

Its proposed effects on recovery should be evaluated with controlled human studies rather than inferred from antioxidant markers alone.

4.5 Urolithin A: Targeting mitochondrial quality control

One of the more interesting translational candidates is urolithin A, a gut microbiome-derived metabolite associated with enhanced mitophagy in experimental systems.

In a randomized trial involving 66 older adults aged 65–90 years, urolithin A improved some muscle endurance measures. However, between-group differences in the primary outcomes—six-minute walking distance and maximal muscle ATP production—were not statistically significant.

A separate randomized, placebo-controlled study published in Nature Aging in October 2025 investigated 50 middle-aged adults receiving 1,000 mg/day for four weeks.

The intervention was associated with changes in CD8⁺ T-cell populations, fatty-acid oxidation capacity, mitochondrial biogenesis-related measures, and selected immune functions. These results are relevant to the relationship between mitochondrial quality control and immunological aging.

However, a 2026 systematic review of five small, short-duration human randomized trials concluded that the overall evidence for improved physical performance is still inconclusive and of limited certainty.

Thus, urolithin A is a credible research candidate, but it is not yet established as a treatment for age-related frailty or impaired clinical recovery.

4.6 Mitochondria-targeted peptides: Elamipretide

Elamipretide is a mitochondria-targeted peptide that interacts with cardiolipin, a lipid important for inner mitochondrial membrane architecture and respiratory-chain function.

A significant regulatory development occurred on September 19, 2025, when the US FDA granted accelerated approval to elamipretide, marketed as Forzinity, for improving muscle strength in patients with Barth syndrome weighing at least 30 kg.

This matters because Barth syndrome is a disease associated with mitochondrial cardiolipin abnormalities.

It demonstrates that targeting a specific mitochondrial defect can lead to a disease-specific approved therapy.

However, the approval does not establish efficacy for normal aging, sarcopenia, general fatigue, or recovery after illness.

Elamipretide therefore provides an important example of mitochondrial medicine reaching clinical practice, while its broader geriatric applications remain unproven.

4.7 Additional experimental interventions

Several further approaches may become relevant to mitochondrial recovery medicine:

The major lesson is that mitochondrial therapies should not be judged simply by whether they increase ATP or reduce inflammation.

They should be judged by whether they improve clinically meaningful recovery without compromising normal defense mechanisms, tissue function, or long-term safety.

5. The MITO RISING Three Arrows within a mitochondrial recovery model

The established MITO RISING conceptual framework can be organized as follows.

The importance of this model is not that three compounds alone can reverse aging.

Its value is that mitochondrial interventions can be grouped according to the distinct biological requirements for recovery.

A more complete future framework could integrate three additional processes:

QUALITY CONTROL — removal and replacement of dysfunctional mitochondria.

RESOLUTION — termination of inflammatory and cellular stress responses.

RENEWAL — regeneration and restoration of tissue-level function.

In other words, the therapeutic sequence becomes:

Signal → Mobilize capacity → Protect → Clear damage → Resolve stress → Renew function.

This is a hypothesis that could guide experimental design and future clinical studies.

6. From mitochondrial dysfunction to the Recovery Clock

This is where Recovery Capacity Theory could make an original contribution to aging medicine.

Most conventional biomarkers evaluate the state of an organism at a particular moment.

Mitochondrial recovery medicine should also measure how the organism responds over time.

A static ATP concentration, NAD⁺ level, or mitochondrial DNA copy number may provide useful mechanistic information, but none independently establishes the ability to recover from a challenge.

A Recovery Clock would instead examine the kinetics of biological adaptation and restoration.

A proposed multidimensional Recovery Clock

An important distinction is that these variables do not all measure the same underlying phenomenon.

Heart-rate recovery primarily reflects autonomic and cardiovascular physiology. Phosphocreatine recovery provides a more proximal measure of muscle oxidative metabolism. Circulating mtDNA is not a specific or standardized measure of mitochondrial dysfunction.

The research challenge is to determine which combination of measurements best predicts meaningful outcomes.

Recovery Capacity as a dynamic variable

The rate constant and recovery plateau capture two different properties.

A person can recover quickly but incompletely. Another may recover slowly yet eventually return to baseline.

Both dimensions matter.

For Recovery Clock development, further variables could include recovery time to a defined threshold, the area under the deficit curve, and variability across repeated challenges.

These metrics could ultimately be combined with biological age measures, including epigenetic clocks.

The crucial validation question would be whether they predict future disability, hospitalization, recovery after illness, or other clinically relevant outcomes better than existing measurements.

7. A proposed clinical research program for Mitochondrial Recovery Medicine

For MITO RISING and MitoQure, a practical next step would be to develop a prospective study designed to test the association between mitochondrial function and recovery capacity.

Phase 1 — Establish a recovery phenotype

Enroll a cohort of approximately 100–150 middle-aged and older adults, potentially including healthy participants and those with early frailty.

Assess baseline functional status, habitual activity, sleep, metabolic health, medication use, and established frailty indicators.

Use a carefully standardized, low-risk physical challenge, such as a supervised submaximal exercise protocol.

Measure heart-rate recovery, functional performance, and metabolic responses. A research subset could undergo more specialized mitochondrial assessments, such as ³¹P-MRS or validated ex-vivo respiratory measurements.

Follow participants longitudinally to determine whether the response profiles predict clinical outcomes.

Phase 2 — Validate the mitochondrial contribution

Evaluate associations between recovery kinetics and measurements of mitochondrial respiratory function, redox regulation, inflammatory signaling, and quality control.

The objective is to distinguish whether mitochondrial measures independently predict recovery after adjustment for fitness, age, disease burden, and other confounders.

Ideally, mitochondrial function would be tested not merely as a correlated biomarker but as a potential mediator of functional recovery.

Phase 3 — Test interventions

Conduct randomized studies of interventions with biologically plausible mitochondrial targets.

A strong initial comparison would involve a standardized combined exercise intervention against an appropriate control because exercise already has substantial clinical evidence.

Candidate supplements or molecular interventions could then be studied separately or in factorial designs.

The MITO RISING Three Arrows could be evaluated only after establishing suitable safety, dosing, regulatory, and feasibility protocols. They should not initially be treated as an already effective combination.

A clinically relevant primary endpoint could be a validated change in physical function or a prespecified recovery-kinetics measure. ATP, NAD⁺, mitochondrial turnover markers, and inflammatory measurements would serve as mechanistic secondary outcomes.

Phase 4 — Develop and validate the Recovery Clock

Its clinical validity would require independent cohorts, calibration, assessment of reproducibility, demonstration of incremental predictive value, and testing across different ages, sexes, diseases, and functional states.

8. What this could change in clinical medicine

The central promise of mitochondrial recovery medicine is not simply that mitochondria may become new pharmaceutical targets.

It is that the success of treatment could be evaluated through a different biological and clinical question.

Traditional medicine asks:

Has the disease been controlled?

Recovery-oriented medicine adds:

Has the person recovered the ability to function, adapt, and respond to future stress?

These questions are complementary.

For an older patient recovering from pneumonia, controlling infection is essential. But the restoration of walking ability, muscle strength, appetite, metabolic stability, sleep, and independence is also clinically important.

Mitochondria participate in many of the physiological processes required for that restoration.

The relevant therapeutic goal is therefore not to maximize mitochondrial activity indiscriminately.

It is to restore appropriate mitochondrial function within the larger biological systems that enable recovery.

This includes understanding when mitochondria should increase energy production, when they should initiate stress responses, when damaged organelles should be removed, and when those responses should terminate.

9. Scientific synthesis: Recovery requires both repair and resolution

Perhaps the most important hypothesis emerging from this framework is that age-related mitochondrial dysfunction has two connected consequences.

First, it can reduce the energy and metabolic flexibility needed to repair damage.

Second, it can sustain stress and inflammatory signals that prevent successful resolution.

These processes may reinforce each other.

This leads to a potentially important refinement of Recovery Capacity Theory:

Aging may involve not only a decline in the ability to repair damage, but also a progressive decline in the ability to terminate stress responses and restore biological homeostasis.

Under this interpretation, effective mitochondrial therapy would require three coordinated capacities:

Energetic capacity — enough metabolic reserve to support repair.

Adaptive capacity — sufficient flexibility and quality control to respond to changing conditions.

Resolution capacity — the ability to end the stress response once restoration has been achieved.

Together, these could form a testable biological foundation for Mitochondrial Recovery Medicine.

10. Conclusion — From extending lifespan to restoring recovery capacity

Mitochondrial research is revealing a more complex picture of aging.

The aging mitochondrion is not simply a declining energy generator.

It is part of a changing system of metabolism, immunity, inflammation, cellular maintenance, and tissue renewal.

Exercise provides the strongest immediately actionable evidence for supporting mitochondrial and functional health in aging. Urolithin A, NAD⁺ precursors, mitochondrial peptides, and other targeted interventions offer varying degrees of promise, but most still require stronger evidence of meaningful recovery benefits in humans.

The next challenge is to connect molecular mechanisms with measurable functional outcomes.

That is where Recovery Capacity Theory has the potential to become more than an explanatory concept.

It could become a research framework for discovering which biological functions allow people to recover, how those functions change with age, and whether targeted interventions can restore them.

The goal of mitochondrial medicine is not simply to produce more energy.

It is to restore the biological capacity to respond, repair, resolve, and renew.

And ultimately:

The future of aging medicine may be measured not only by how slowly we decline, but by how effectively we recover.

MITO RISING — THE AGE OF RECOVERY

Aging is not time. It is the loss of recovery capacity.

Selected scientific references

1. Gallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026.
2. Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging. 2025.
3. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022.
4. Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. Frontiers in Nutrition. 2026.
5. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Sports Medicine. 2024.
6. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. September 19, 2025.

The most consequential next research question for MITO RISING is whether improving mitochondrial quality control and stress-response resolution can demonstrably improve the speed and completeness of recovery in older humans. That is the experiment that could connect mitochondrial biology, Recovery Capacity Theory, and a clinically validated Recovery Clock.

© 2026 Shigeki Takemoto / MitoQure